130 related articles for article (PubMed ID: 10778942)
1. Cytochrome P-450 and other determinants of pharmacokinetics, toxicity, and efficacy in humans.
Collins JM
Clin Cancer Res; 2000 Apr; 6(4):1203-4. PubMed ID: 10778942
[No Abstract] [Full Text] [Related]
2. Predicting drug interactions in vivo from experiments in vitro. Human studies with paclitaxel and ketoconazole.
Jamis-Dow CA; Pearl ML; Watkins PB; Blake DS; Klecker RW; Collins JM
Am J Clin Oncol; 1997 Dec; 20(6):592-9. PubMed ID: 9391548
[TBL] [Abstract][Full Text] [Related]
3. Erythromycin breath test.
Watkins PB
Clin Pharmacol Ther; 2000 May; 67(5):577-8. PubMed ID: 10824637
[No Abstract] [Full Text] [Related]
4. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.
Hirth J; Watkins PB; Strawderman M; Schott A; Bruno R; Baker LH
Clin Cancer Res; 2000 Apr; 6(4):1255-8. PubMed ID: 10778948
[TBL] [Abstract][Full Text] [Related]
5. Increased activity of CYP3A enzyme in primary cultures of rat hepatocytes treated with docetaxel: comparative evaluation with paclitaxel.
Nallani SC; Genter MB; Desai PB
Cancer Chemother Pharmacol; 2001 Aug; 48(2):115-22. PubMed ID: 11561777
[TBL] [Abstract][Full Text] [Related]
6. Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization.
Chiou WL; Jeong HY; Wu TC; Ma C
Clin Pharmacol Ther; 2001 Oct; 70(4):305-10. PubMed ID: 11673745
[No Abstract] [Full Text] [Related]
7. Effects of ketoconazole on the erythromycin breath test and the dapsone recovery ratio.
Kinirons MT; Krivoruk Y; Wilkinson GR; Wood AJ
Br J Clin Pharmacol; 1999 Feb; 47(2):223-5. PubMed ID: 10190659
[No Abstract] [Full Text] [Related]
8. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies.
Goh BC; Lee SC; Wang LZ; Fan L; Guo JY; Lamba J; Schuetz E; Lim R; Lim HL; Ong AB; Lee HS
J Clin Oncol; 2002 Sep; 20(17):3683-90. PubMed ID: 12202670
[TBL] [Abstract][Full Text] [Related]
9. Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy.
Martínez C; García-Martín E; Pizarro RM; García-Gamito FJ; Agúndez JA
Br J Cancer; 2002 Sep; 87(6):681-6. PubMed ID: 12237780
[TBL] [Abstract][Full Text] [Related]
10. Early postoperative erythromycin breath test correlates with hepatic cytochrome P4503A activity in liver transplant recipients.
Schmidt LE; Olsen AK; Stentoft K; Rasmussen A; Kirkegaard P; Dalhoff K
Clin Pharmacol Ther; 2001 Nov; 70(5):446-54. PubMed ID: 11719731
[TBL] [Abstract][Full Text] [Related]
11. Mdr1 limits CYP3A metabolism in vivo.
Lan LB; Dalton JT; Schuetz EG
Mol Pharmacol; 2000 Oct; 58(4):863-9. PubMed ID: 10999959
[TBL] [Abstract][Full Text] [Related]
12. Hepatic cytochrome P-4503A (CYP3A) activity in the elderly.
Hunt CM; Westerkam WR; Stave GM; Wilson JA
Mech Ageing Dev; 1992 Jun; 64(1-2):189-99. PubMed ID: 1630156
[TBL] [Abstract][Full Text] [Related]
13. Antisense strategies for redirection of drug metabolism: using paclitaxel as a model.
Arora V
Methods Mol Med; 2005; 106():273-92. PubMed ID: 15375322
[No Abstract] [Full Text] [Related]
14. Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients.
Cakaloglu Y; Tredger JM; Devlin J; Williams R
Hepatology; 1994 Aug; 20(2):309-16. PubMed ID: 7519161
[TBL] [Abstract][Full Text] [Related]
15. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.
Wacher VJ; Wu CY; Benet LZ
Mol Carcinog; 1995 Jul; 13(3):129-34. PubMed ID: 7619215
[No Abstract] [Full Text] [Related]
16. Genetics. SNP-ing drugs to size.
Gura T
Science; 2001 Jul; 293(5530):595. PubMed ID: 11474082
[No Abstract] [Full Text] [Related]
17. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men.
Kinirons MT; O'Shea D; Downing TE; Fitzwilliam AT; Joellenbeck L; Groopman JD; Wilkinson GR; Wood AJ
Clin Pharmacol Ther; 1993 Dec; 54(6):621-9. PubMed ID: 8275617
[TBL] [Abstract][Full Text] [Related]
18. Grapefruits and drugs: when is statistically significant clinically significant?
Abernethy DR
J Clin Invest; 1997 May; 99(10):2297-8. PubMed ID: 9153265
[No Abstract] [Full Text] [Related]
19. Role of human CYP3A and P-glycoprotein on the absorption of drugs.
van de Waterbeemd H
Eur J Pharm Sci; 2000 Nov; 12(1):1. PubMed ID: 11121728
[No Abstract] [Full Text] [Related]
20. The effect of spironolactone treatment on the cytochrome P450-mediated metabolism of the pyrrolizidine alkaloid senecionine by hepatic microsomes from rats and guinea pigs.
Chung WG; Buhler DR
Toxicol Appl Pharmacol; 1994 Aug; 127(2):314-9. PubMed ID: 8048076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
